Skip to content

Trial Summary

This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors



ACTRN/NCT /ethics:


Scientific title:

A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Sponsor / Cooperative group:

Antengene Therapeutics Limited

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 Years and older
Tumour Stream -
Cancer StageLocally Advanced, Metastatic or Widespread
Anticipated Start Date2022-12-31
Anticipated End Date2024-08-30

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting